… Yeo reduced the dose of erlotinib down to 25 mg/day in a retrospective study and achieved
a similar or even better prognosis compared with the standard dose. [67] Similar results were …

… first-generation EGFR TKIs (eg, gefitinib and erlotinib) is approximately 10 to 12 months.10, …
, is a superior first-line therapy according to the FLAURA study, 11 , 12 there is no standard …

… No study has compared these two generations of EGFR-TKIs in this patient population.
Herein, we conducted a retrospective study to assess the efficacy of gefitinib/erlotinib and afatinib …

… A large cohort study based on the Taiwan Cancer Registry, conducted in 2011–2015,
compared the efficacy of three different TKIs—gefitinib, erlotinib, and afatinin. The results showed …

… : Erlotinib has proven activity in pretreated patients with advanced non–small cell lung cancer
(NSCLC). We evaluated erlotinib … Conclusions: Erlotinib shows significant antitumor activity …

… , the FLAURA trial compared osimertinib with erlotinib or gefitinib in … More recently, a
retrospective multicenter analysis in … A retrospective study of erlotinib in this setting also revealed …

… with then regularly available TKIs (gefitinib, erlotinib or afatinib). … its retrospective and
non-interventional nature, this study … erlotinib, we observed a poorer adjusted survival for gefitinib …

… We conducted a phase II study of erlotinib after failure of gefitinib treatment in patients with …
study who benefited from erlotinib. In our study, of the 15 patients who benefited from gefitinib, …

… trial 4 and this meta-analysis reported similar risks for diarrhea with both erlotinib and gefitinib.
… A retrospective study of the Japanese population reports a risk for pneumonitis of 3.5% …

… study is to evaluate the efficacy of erlotinib, another EGFR-TKI, after failed first-line use of
gefitinib… Therefore, we conducted a retrospective review of our single institutional experience of …